Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| RNA, Messenger | 11 | 2021 | 5131 | 1.68 | Why? |
| Nucleosides | 2 | 2018 | 221 | 1.14 | Why? |
| Therapeutic Misconception | 1 | 2021 | 4 | 0.92 | Why? |
| Germinal Center | 2 | 2020 | 332 | 0.75 | Why? |
| T-Lymphocytes, Helper-Inducer | 2 | 2020 | 497 | 0.71 | Why? |
| Hemagglutinins | 1 | 2018 | 143 | 0.69 | Why? |
| Vaccines, Synthetic | 5 | 2021 | 3231 | 0.64 | Why? |
| Nanoparticles | 9 | 2021 | 2040 | 0.57 | Why? |
| Influenza A Virus, H5N1 Subtype | 1 | 2018 | 492 | 0.55 | Why? |
| Viral Vaccines | 5 | 2021 | 7560 | 0.48 | Why? |
| Lipids | 4 | 2021 | 1079 | 0.48 | Why? |
| Vaccines, Subunit | 1 | 2018 | 1088 | 0.46 | Why? |
| Orthomyxoviridae | 1 | 2018 | 1168 | 0.39 | Why? |
| Mice, Inbred BALB C | 6 | 2021 | 5814 | 0.39 | Why? |
| B-Lymphocytes | 3 | 2020 | 4418 | 0.34 | Why? |
| Antitubercular Agents | 3 | 2019 | 775 | 0.34 | Why? |
| Macaca mulatta | 3 | 2020 | 3716 | 0.27 | Why? |
| Zika Virus | 1 | 2017 | 1924 | 0.27 | Why? |
| Tuberculosis, Pulmonary | 3 | 2019 | 1171 | 0.26 | Why? |
| Antibodies, Neutralizing | 7 | 2021 | 25288 | 0.26 | Why? |
| Zika Virus Infection | 1 | 2017 | 1920 | 0.25 | Why? |
| Tuberculosis | 4 | 2020 | 2895 | 0.24 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 2 | 2020 | 66 | 0.23 | Why? |
| HIV-1 | 1 | 2017 | 3365 | 0.23 | Why? |
| Ions | 1 | 2021 | 73 | 0.23 | Why? |
| Dendrimers | 1 | 2021 | 104 | 0.21 | Why? |
| HIV Infections | 7 | 2020 | 11620 | 0.21 | Why? |
| Ethambutol | 1 | 2019 | 34 | 0.21 | Why? |
| Mutation | 1 | 2020 | 12376 | 0.20 | Why? |
| Mice | 8 | 2021 | 21357 | 0.20 | Why? |
| Lung Injury | 2 | 2020 | 919 | 0.20 | Why? |
| Surface-Active Agents | 1 | 2021 | 267 | 0.19 | Why? |
| Vaccines | 1 | 2018 | 3692 | 0.18 | Why? |
| Mice, Inbred C57BL | 3 | 2021 | 5542 | 0.18 | Why? |
| Animals | 12 | 2021 | 78931 | 0.18 | Why? |
| Pyrazinamide | 1 | 2017 | 38 | 0.18 | Why? |
| Apyrase | 1 | 2017 | 39 | 0.17 | Why? |
| Airway Remodeling | 1 | 2018 | 111 | 0.17 | Why? |
| Mice, Inbred NOD | 1 | 2017 | 134 | 0.17 | Why? |
| Injections, Intradermal | 1 | 2017 | 102 | 0.17 | Why? |
| Mice, SCID | 1 | 2017 | 225 | 0.16 | Why? |
| Madin Darby Canine Kidney Cells | 1 | 2018 | 640 | 0.16 | Why? |
| Antigens | 1 | 2018 | 267 | 0.15 | Why? |
| Drug Carriers | 1 | 2021 | 590 | 0.15 | Why? |
| RNA Stability | 1 | 2017 | 285 | 0.15 | Why? |
| Protein Subunits | 1 | 2018 | 755 | 0.14 | Why? |
| Rifampin | 1 | 2017 | 276 | 0.14 | Why? |
| Common Cold | 1 | 2021 | 645 | 0.14 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.14 | Why? |
| Rabbits | 1 | 2018 | 1171 | 0.14 | Why? |
| Adenoviridae | 1 | 2020 | 1151 | 0.14 | Why? |
| Recombination, Genetic | 1 | 2021 | 1265 | 0.13 | Why? |
| Genetic Vectors | 1 | 2020 | 1600 | 0.13 | Why? |
| Immunization, Passive | 2 | 2020 | 10067 | 0.12 | Why? |
| Ferrets | 1 | 2018 | 1201 | 0.12 | Why? |
| Respiration | 1 | 2018 | 729 | 0.12 | Why? |
| Meningitis, Cryptococcal | 1 | 2013 | 79 | 0.12 | Why? |
| Adjuvants, Immunologic | 2 | 2021 | 1709 | 0.12 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.12 | Why? |
| Glycoproteins | 1 | 2017 | 615 | 0.11 | Why? |
| Antigens, CD | 1 | 2017 | 984 | 0.11 | Why? |
| Amphotericin B | 1 | 2013 | 256 | 0.11 | Why? |
| Dogs | 1 | 2018 | 2529 | 0.11 | Why? |
| Cells, Cultured | 2 | 2020 | 5835 | 0.11 | Why? |
| Gene Expression | 1 | 2021 | 3332 | 0.11 | Why? |
| HIV Antibodies | 1 | 2017 | 776 | 0.11 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.10 | Why? |
| HEK293 Cells | 2 | 2021 | 8394 | 0.10 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2013 | 260 | 0.10 | Why? |
| Anti-HIV Agents | 3 | 2017 | 2209 | 0.10 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.10 | Why? |
| HIV | 3 | 2020 | 1116 | 0.10 | Why? |
| Flow Cytometry | 1 | 2018 | 2393 | 0.10 | Why? |
| Mice, Transgenic | 1 | 2017 | 2739 | 0.10 | Why? |
| Antibodies, Monoclonal | 2 | 2020 | 8041 | 0.10 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.10 | Why? |
| CD4-Positive T-Lymphocytes | 2 | 2021 | 4545 | 0.09 | Why? |
| Viral Envelope Proteins | 2 | 2017 | 3539 | 0.09 | Why? |
| Neoplasms | 1 | 2018 | 17251 | 0.09 | Why? |
| Gastrointestinal Tract | 1 | 2017 | 1113 | 0.09 | Why? |
| Botswana | 2 | 2019 | 98 | 0.09 | Why? |
| Transfection | 2 | 2021 | 864 | 0.09 | Why? |
| Coinfection | 2 | 2019 | 6820 | 0.09 | Why? |
| Binding Sites | 1 | 2020 | 6201 | 0.09 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.08 | Why? |
| Biological Availability | 2 | 2019 | 388 | 0.08 | Why? |
| Neutralization Tests | 1 | 2020 | 6698 | 0.08 | Why? |
| Vaccination | 4 | 2021 | 19050 | 0.08 | Why? |
| Antibody Formation | 1 | 2018 | 4038 | 0.07 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.07 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2020 | 5837 | 0.07 | Why? |
| Antigens, Viral | 2 | 2020 | 6298 | 0.06 | Why? |
| CD4 Lymphocyte Count | 2 | 2020 | 1517 | 0.06 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.06 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.06 | Why? |
| Female | 11 | 2021 | 380317 | 0.06 | Why? |
| Humans | 21 | 2021 | 930598 | 0.06 | Why? |
| Antifungal Agents | 1 | 2013 | 1828 | 0.06 | Why? |
| Spectrum Analysis | 1 | 2021 | 112 | 0.06 | Why? |
| Drug Liberation | 1 | 2021 | 141 | 0.05 | Why? |
| Immunity, Heterologous | 1 | 2021 | 129 | 0.05 | Why? |
| Polysorbates | 1 | 2020 | 125 | 0.05 | Why? |
| Lymphocyte Activation | 2 | 2020 | 2742 | 0.05 | Why? |
| Squalene | 1 | 2020 | 196 | 0.05 | Why? |
| Lectins, C-Type | 1 | 2003 | 405 | 0.05 | Why? |
| Tissue Distribution | 1 | 2021 | 483 | 0.05 | Why? |
| Cell Adhesion Molecules | 1 | 2003 | 472 | 0.05 | Why? |
| Macaca | 1 | 2021 | 388 | 0.05 | Why? |
| Phylogeny | 1 | 2018 | 13341 | 0.05 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 952 | 0.05 | Why? |
| Drug Compounding | 1 | 2021 | 386 | 0.05 | Why? |
| Liposomes | 1 | 2021 | 334 | 0.05 | Why? |
| Proof of Concept Study | 1 | 2021 | 696 | 0.05 | Why? |
| Cross Protection | 1 | 2021 | 373 | 0.05 | Why? |
| Injections, Intramuscular | 1 | 2021 | 800 | 0.05 | Why? |
| Receptors, Cell Surface | 1 | 2003 | 586 | 0.05 | Why? |
| Bacterial Translocation | 1 | 2017 | 39 | 0.04 | Why? |
| Hydrogen-Ion Concentration | 1 | 2021 | 993 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2021 | 1115 | 0.04 | Why? |
| Spleen | 1 | 2021 | 877 | 0.04 | Why? |
| Prospective Studies | 5 | 2020 | 43301 | 0.04 | Why? |
| Administration, Intranasal | 1 | 2021 | 1132 | 0.04 | Why? |
| Recombinant Fusion Proteins | 1 | 2021 | 919 | 0.04 | Why? |
| Molecular Structure | 1 | 2021 | 1539 | 0.04 | Why? |
| Trachea | 1 | 2021 | 894 | 0.04 | Why? |
| Ebolavirus | 1 | 2003 | 834 | 0.04 | Why? |
| Lung | 3 | 2021 | 31049 | 0.04 | Why? |
| Immunogenicity, Vaccine | 2 | 2021 | 4624 | 0.04 | Why? |
| Adult | 7 | 2020 | 244371 | 0.03 | Why? |
| Lymph Nodes | 1 | 2021 | 1060 | 0.03 | Why? |
| Alkynes | 1 | 2013 | 98 | 0.03 | Why? |
| Furin | 1 | 2020 | 1054 | 0.03 | Why? |
| Benzoxazines | 1 | 2013 | 103 | 0.03 | Why? |
| Colony Count, Microbial | 1 | 2013 | 177 | 0.03 | Why? |
| Organophosphonates | 1 | 2013 | 85 | 0.03 | Why? |
| Disease Models, Animal | 2 | 2021 | 10998 | 0.03 | Why? |
| Deoxycytidine | 1 | 2013 | 116 | 0.03 | Why? |
| Betacoronavirus | 3 | 2021 | 204454 | 0.03 | Why? |
| Emtricitabine | 1 | 2013 | 202 | 0.03 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.03 | Why? |
| Male | 7 | 2021 | 367725 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2021 | 29620 | 0.03 | Why? |
| Immunization | 1 | 2020 | 2019 | 0.03 | Why? |
| Cyclopropanes | 1 | 2013 | 332 | 0.03 | Why? |
| Recombinant Proteins | 1 | 2020 | 3786 | 0.03 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 1458 | 0.03 | Why? |
| Adenine | 1 | 2013 | 463 | 0.03 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.03 | Why? |
| South Africa | 1 | 2020 | 3326 | 0.02 | Why? |
| Tenofovir | 1 | 2013 | 449 | 0.02 | Why? |
| Middle Aged | 4 | 2020 | 270681 | 0.02 | Why? |
| Drug Design | 1 | 2021 | 2627 | 0.02 | Why? |
| Pandemics | 3 | 2021 | 389249 | 0.02 | Why? |
| Mycobacterium tuberculosis | 1 | 2018 | 1164 | 0.02 | Why? |
| Anti-Retroviral Agents | 1 | 2017 | 1099 | 0.02 | Why? |
| Epitopes | 1 | 2020 | 4113 | 0.02 | Why? |
| Immunologic Memory | 1 | 2020 | 3362 | 0.02 | Why? |
| Protein Domains | 1 | 2021 | 6563 | 0.02 | Why? |
| Immunotherapy | 1 | 2021 | 2421 | 0.02 | Why? |
| Models, Molecular | 1 | 2021 | 7616 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.02 | Why? |
| Biomarkers | 2 | 2017 | 23361 | 0.02 | Why? |
| Cohort Studies | 2 | 2017 | 36005 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.02 | Why? |
| Coronavirus Infections | 2 | 2021 | 253789 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2021 | 7330 | 0.01 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.01 | Why? |
| Survival Analysis | 1 | 2013 | 7592 | 0.01 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.01 | Why? |
| Glycosylation | 1 | 2003 | 1255 | 0.01 | Why? |
| SARS Virus | 1 | 2021 | 13021 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2021 | 12361 | 0.01 | Why? |
| Polysaccharides | 1 | 2003 | 854 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.01 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.01 | Why? |
| Cell Line | 1 | 2003 | 12040 | 0.01 | Why? |
| Treatment Outcome | 1 | 2013 | 51732 | 0.00 | Why? |
| Aged | 1 | 2017 | 215776 | 0.00 | Why? |
Weissman's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(180)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(161)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_